10-K: Citius Oncology: LYMPHIR Launch Amidst Going Concern

Citius Oncology launched its lead product LYMPHIR in December 2025, but faces substantial doubt about its ability to continue as a going concern due to recurring losses and a need for significant additional funding.

Summary

• Citius Oncology is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies, with its lead product being LYMPHIR (denileukin diftitox).
• LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for persistent or recurrent Cutaneous T-Cell Lymphoma (CTCL), received FDA approval in August 2024 and was commercially launched in the U.S. in December 2025.
• The company estimates the addressable U.S. market for LYMPHIR to exceed $400 million, believing it is underserved by existing treatments.
• Citius Oncology reported a net loss of $24,761,369 for the fiscal year ended September 30, 2025, an increase from $21,148,747 in the prior year, and has an accumulated deficit of $64,039,956.
• The company's independent registered public accounting firm's report includes an explanatory paragraph stating substantial doubt about its ability to continue as a going concern beyond March 2026.
• As of September 30, 2025, cash and cash equivalents were $3,924,908, and the company had a negative working capital of approximately $21.9 million.
• Citius Oncology relies heavily on funding and shared services from its majority shareholder, Citius Pharmaceuticals, Inc. (Citius Pharma), which owns approximately 79% of its common stock.
• Preliminary results from a Phase 1 trial combining LYMPHIR with Pembrolizumab in recurrent solid tumors showed an overall response rate (ORR) of 27% and a clinical benefit rate (CBR) of 33% among evaluable patients, with a median progression-free survival (PFS) of 57 weeks for those achieving clinical benefit.
• LYMPHIR has been included in the National Comprehensive Cancer Network (NCCN) guidelines with a Category 2A recommendation and assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) by CMS, which is expected to facilitate reimbursement.

Sentiment

Score: 3

Explanation: While the company achieved a significant milestone with FDA approval and commercial launch of its lead product LYMPHIR, and showed promising early clinical data for a combination therapy, its severe financial distress, including recurring losses, a substantial accumulated deficit, negative working capital, and an explicit 'going concern' warning from its auditor, presents an overwhelming risk. The continuous need for capital raises and reliance on its parent company for funding and services indicate high financial instability.

Positives

• FDA approval of LYMPHIR (denileukin diftitox) in August 2024 for the treatment of persistent or recurrent CTCL.
• Commercial launch of LYMPHIR in the U.S. in December 2025, with initial commercial orders placed and filled.
• Inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines with a Category 2A recommendation, which is expected to assist in obtaining coverage and reimbursement.
• Assignment of a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) by CMS in February 2025, providing coding clarity and facilitating reimbursement.
• Promising preliminary results from a Phase 1 clinical trial combining LYMPHIR with Pembrolizumab in recurrent solid tumors, demonstrating a 27% overall response rate and 33% clinical benefit rate among evaluable patients, including those who failed prior checkpoint inhibitors.
• Established sales, marketing, and distribution capabilities through third-party organizations and agreements with major wholesalers (Cardinal Health, Cencora, McKesson Corporation) and a commercialization services provider (EVERSANA).
• Entered into international distribution agreements for Named Patient Programs in Europe, South America, and the Middle East, expanding potential market access.

Negatives

• The independent registered public accounting firm's report includes an explanatory paragraph stating substantial doubt about the company's ability to continue as a going concern.
• Incurred a net loss of $24,761,369 for the fiscal year ended September 30, 2025, an increase from $21,148,747 in the prior year, and has a history of net losses.
• Accumulated deficit of $64,039,956 as of September 30, 2025.
• Negative working capital of approximately $21.9 million as of September 30, 2025.
• Requires substantial additional funding beyond March 2026 to continue operations and successfully commercialize LYMPHIR, with no assurance of availability on acceptable terms.
• Significant outstanding commitments include $38.4 million to third-party suppliers and manufacturers and $22.7 million under license agreements as of September 30, 2025.
• High reliance on Citius Pharma for funding and operational functions, which creates potential conflicts of interest and challenges if Citius Pharma ceases support.
• The market price of common stock is highly volatile, and future sales of a substantial number of shares (e.g., by Citius Pharma) may cause price decline and dilution.
• Risk of delisting from Nasdaq if continued listing requirements, such as maintaining a minimum stock price of $1.00, are not met.

Risks

• Substantial doubt about the ability to continue as a going concern.
• Requirement for substantial additional funding in the near future, which may not be available on acceptable terms or at all, potentially forcing delays, reductions, or termination of commercialization efforts and business operations.
• History of net losses and expectation to incur losses for the foreseeable future, with no guarantee of generating revenues or achieving profitability.
• Ongoing exploration of alternative strategic paths may not result in transactions, and the process or conclusion could adversely affect stock price; potential dissolution and liquidation if a strategic transaction is not successfully completed.
• Unproven business strategy and limited operating history for the successful commercialization of LYMPHIR or any future product candidates.
• Obligation to make milestone payments to licensors (Eisai and Dr. Reddys) for LYMPHIR intellectual property, which could adversely affect profitability; material breach of license agreements could lead to termination.
• Reliance exclusively on third parties for formulation and manufacturing, with failure to abide by contractual obligations (including timely payment) potentially resulting in delays or loss of necessary support.
• Significant risks in commercialization efforts of LYMPHIR and development of any future product candidates, including potential ineffectiveness or harmful side effects in trials, or failure to achieve market acceptance.
• LYMPHIR may not gain market acceptance among physicians, patients, healthcare payers, or the medical community, potentially failing to generate significant revenue.
• Inability to create a market for LYMPHIR or any future product candidate if marketing, sales, and distribution capabilities are not successfully established.
• Projections regarding the market opportunity for LYMPHIR may not be accurate, and the actual market may be smaller than estimated.
• Ability to generate product revenues will be diminished if LYMPHIR sells for inadequate prices or patients are unable to obtain adequate levels of reimbursement.
• Highly competitive markets in which the company operates, with many competitors having substantially greater resources and experience.
• Healthcare reform measures could hinder or prevent LYMPHIR's commercial success.
• Any termination, breach by, or conflict with strategic partners could harm the business.
• Reliance on the significant experience and specialized expertise of executive management and other key personnel; loss or inability to successfully hire successors could harm the business.
• Inability to retain or hire additional qualified personnel could harm business growth.
• Subject to information technology and cyber-security threats, which could have an adverse effect on business and results of operations.
• Results of pre-clinical studies and completed clinical trials are not necessarily predictive of future results, and future product candidates may not have favorable results in later studies or trials.
• Ongoing regulatory obligations and restrictions following LYMPHIR's approval may result in significant expense and limit commercialization ability.
• Potential for substantial damage awards if product liability claims are successful.
• Might not obtain necessary U.S. or foreign regulatory approvals to commercialize any future product candidates.
• Failure to protect intellectual property may adversely affect business; risk of infringing third-party rights.
• The market price of common stock is highly volatile, and future sales of a substantial number of shares may cause the price to decline.
• Failure to meet Nasdaq continued listing requirements could result in a suspension or delisting of the common stock.
• As a controlled company under Nasdaq standards, the company may rely on exemptions from certain governance requirements, limiting protections afforded to stockholders.
• Provisions in the Certificate of Incorporation, Bylaws, and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.
• If estimates or judgments relating to critical accounting policies prove incorrect or financial reporting standards change, results of operations could be adversely affected.
• Conflicts of interest may arise from the relationship with Citius Pharma, as many directors and officers hold dual roles.
• Difficulty replacing important corporate functions if Citius Pharma ceases providing services, and obligation to pay fees under the A&R Shared Services Agreement and repay a promissory note to Citius Pharma.
• Financial statements may not necessarily be indicative of conditions that would have existed if the company had been operated as an unaffiliated entity of Citius Pharma.
• Controlled by Citius Pharma, whose interests may differ from those of public stockholders.

Future Outlook

The company expects to incur losses for the foreseeable future and requires substantial additional funding beyond March 2026 to continue operations and successfully commercialize LYMPHIR. The success of LYMPHIR is dependent on market acceptance, adequate pricing, reimbursement, and effective sales and marketing. The company is also exploring LYMPHIR's potential in immuno-oncology combination therapies through ongoing investigator-initiated trials, with preliminary results for one trial anticipated in the first quarter of 2026.

Management Comments

• "We believe there is an attractive and growing market for LYMPHIR, estimated to exceed $400 million, that is underserved by existing treatments."
• "The Company intends to commercialize our products independently in the U.S., and partner to market products outside of the U.S."
• "The Company is confident that all drug substance and drug product materials meet or will meet specifications as agreed with the FDA."
• "The Company also believes our contract manufacturers have sufficient capacity to support demand for LYMPHIR and any future clinical phase and approved products as our business grows."
• "Our management believes that inflation has not had a material effect on our results of operations."

Industry Context

The company operates in the highly competitive biopharmaceutical industry, specifically targeting the rare form of non-Hodgkin lymphoma, Cutaneous T-Cell Lymphoma (CTCL). The market for CTCL treatments is estimated to exceed $400 million and is considered underserved, presenting an opportunity for LYMPHIR. While several approved systemic treatments exist (e.g., Mogamulizumab, Brentuximab vedotin, Romidepsin, Vorinostat), they often have limitations such as toxicity, adverse events, or limited duration of response. Citius Oncology's strategy focuses on innovative therapies with reduced development and clinical risks, including new formulations of previously approved drugs or expanded indications. The exploration of LYMPHIR in immuno-oncology combination therapies, particularly with checkpoint inhibitors, aligns with broader industry trends in leveraging synergistic mechanisms to enhance anti-tumor activity and address resistance.

Comparison to Industry Standards

• LYMPHIR is an improved formulation of ONTAK, a previously FDA-approved oncology agent for CTCL, with a comparable safety profile to its predecessor's pivotal study.
• The pivotal trial for LYMPHIR (E7777-G000-302) demonstrated an Objective Response Rate (ORR) of 36.2% (95% CI: 25.0%, 48.7%) in patients with relapsed or refractory Stage I-III CTCL, with 8.7% achieving a Complete Response.
• The company noted a marginal shortfall in the statistical confidence interval (25% actual achievement vs. >25% from the statistical plan) but the FDA accepted the data for tolerability and clinical benefit.
• Preliminary Phase 1 results for LYMPHIR combined with Pembrolizumab in recurrent solid tumors showed an ORR of 27% and a clinical benefit rate of 33% among evaluable patients, with a median progression-free survival of 57 weeks for responders. This included patients who had previously failed checkpoint inhibitors, suggesting potential efficacy in a challenging patient population compared to standard monotherapy approaches.
• Competitors in the systemic treatment of advanced CTCL include Mogamulizumab (Poteligeo), Brentuximab vedotin (Adcetris), Romidepsin (Istodax), and Vorinostat (Zolinza), which are noted to have limitations regarding toxicity, adverse events, or duration of response.

Corporate Governance

Legal Proceedings

• The company is not involved in any litigation that it believes could have a material adverse effect on its financial position or results of operations.
• There are no actions, suits, proceedings, inquiries, or investigations pending or, to the knowledge of executive officers, threatened against the company or its officers or directors.

Related Party Transactions

• Citius Pharmaceuticals, Inc. (Citius Pharma) owns approximately 79% of Citius Oncology's outstanding common stock as of December 10, 2025, making Citius Oncology a controlled company.
• Citius Pharma provides management and scientific services to Citius Oncology under an Amended and Restated Shared Services Agreement, with an aggregate quarterly fee of approximately $940,000 plus reimbursement for out-of-pocket costs.
• For the fiscal year ended September 30, 2025, Citius Pharma charged Citius Oncology $2,201,742 for general and administrative payroll, $1,920,000 for research and development payroll, and $114,185 for shared office space.
• The net amount due to Citius Pharma was $9,513,771 as of September 30, 2025.
• Citius Pharma made a loan to Citius Oncology, evidenced by an unsecured, non-interest bearing promissory note in the principal amount of $3,800,111, repayable in full when Citius Oncology closes capital raises aggregating at least $50 million (amended from $30 million on December 10, 2025).
• All directors (except Joel Mayersohn) and executive officers of Citius Oncology also serve as directors and/or employees of Citius Pharma, creating potential conflicts of interest in decisions that could have different implications for each company.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity offerings, as well as high volatility in the stock price. The 'controlled company' status limits certain corporate governance protections, and Citius Pharma's interests may not always align with those of public shareholders.
• Employees (primarily those seconded from Citius Pharma) are critical to operations, but the company's financial instability could impact long-term employment security if additional funding is not secured.
• Customers (patients and physicians) benefit from the availability of LYMPHIR for CTCL, but market acceptance and consistent reimbursement are crucial for sustained access.
• Suppliers and creditors face risks related to the company's ability to meet its substantial outstanding payment obligations and purchase commitments, which could be jeopardized by funding shortfalls.
• Citius Pharma, as the majority shareholder and primary financial and operational support, bears significant risk related to Citius Oncology's financial performance and continued viability, while also benefiting from potential future success and maintaining strategic control.

Next Steps

• Generate substantial revenue from the sales of LYMPHIR.
• Raise additional capital in the future to support operations beyond March 2026 and continue commercialization efforts for LYMPHIR.
• Continue to evaluate strategic alternatives, including partnerships, joint ventures, mergers, acquisitions, or licensing transactions, to maximize shareholder value.
• Advance development of LYMPHIR for other potential indications, including through ongoing investigator-initiated immuno-oncology trials.
• Obtain medical insurance coverage and adequate reimbursement for LYMPHIR.
• Establish and maintain a favorable competitive position for LYMPHIR in the market.
• Recruit and train additional qualified personnel to manage anticipated growth and increased operational activity.
• Improve operational, financial, and management controls, reporting systems, and procedures.
• Anticipate preliminary results for the Phase 1 trial using E7777 to enhance regulatory T-Cell depletion prior to CAR-T therapy in the first quarter of 2026.
• Potentially extend the license agreement with Eisai for additional 10-year periods by paying a $10 million extension fee.

Key Dates

Recommendation

Despite the significant achievement of FDA approval and the commercial launch of LYMPHIR, coupled with promising early clinical data for combination therapies, Citius Oncology's severe financial condition presents an untenable risk for investors. The independent auditor's 'going concern' warning, a substantial accumulated deficit of over $64 million, and negative working capital of nearly $22 million, underscore a precarious financial state. The company's explicit need for substantial additional capital beyond March 2026, with no guarantee of securing it on favorable terms, indicates a high probability of further significant shareholder dilution or even potential dissolution. While LYMPHIR has market potential, the company's ability to effectively commercialize and sustain operations is severely hampered by its financial instability and heavy reliance on its parent company. A seasoned investor would prioritize capital preservation and exit this position given the overwhelming financial risks.

Keywords

Biopharmaceutical, Oncology, CTCL, LYMPHIR, Denileukin Diftitox, Cancer Treatment, FDA Approval, NASDAQ, Citius Oncology, Rare Disease, Immuno-oncology, Clinical Trials, Financial Report, 10-K, Going Concern